Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

771
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
771
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

470
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
470
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

540
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
540
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

1.1K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

434
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
434
Drug Therapy01:28

Drug Therapy

226
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
226

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oral Clonidine and Brimonidine Eye Drops Attenuated Sertraline Discontinuation Symptoms.

Biological psychiatry·2026
Same author

Increase of the AMPA-evoked response of pyramidal neurons in the rat medial prefrontal cortex following acute administration of ketamine and S-ketamine, but not R-ketamine.

The international journal of neuropsychopharmacology·2026
Same author

Structural and functional neuroimaging correlates of suicidal ideation in treatment-resistant major depressive disorder.

The international journal of neuropsychopharmacology·2026
Same author

Deep learning using electroencephalogram (EEG) data for diagnosing and predicting SSRI response in major depressive disorder.

Communications medicine·2026
Same author

Differentiating suicide risk in treatment-resistant depression: clinical and functional imaging correlates of suicidal ideation and attempt.

NeuroImage. Clinical·2026
Same author

α<sub>5</sub>-GABA<sub>A</sub> allosteric modulation triggers and prolongs dopamine neuronal activity via AMPA receptors.

Journal of psychopharmacology (Oxford, England)·2026

Related Experiment Video

Updated: Jan 6, 2026

Animal Models of Depression - Chronic Despair Model CDM
05:47

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

8.0K

Ketamine for chronic depression: two cautionary tales

Jeanne Talbot1, Jennifer L. Phillips1, Pierre Blier1

  • 1From the The Royal’s Institute of Mental Health Research, Mood Disorders Research Unit, Ottawa, Ont. (Talbot, Phillips, Blier); and the Department of Psychiatry, University of Ottawa, Ottawa, Ont. (Talbot, Phillips, Blier).

Journal of Psychiatry & Neuroscience : JPN
|October 2, 2019
PubMed
Summary

The duration of ketamine's antidepressant effects after treatment cessation is unclear. This commentary explores unexpected data from a pilot study on ketamine infusions for treatment-resistant depression.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.4K
Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
07:52

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Published on: June 2, 2015

12.5K

Related Experiment Videos

Last Updated: Jan 6, 2026

Animal Models of Depression - Chronic Despair Model CDM
05:47

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

8.0K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.4K
Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
07:52

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Published on: June 2, 2015

12.5K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Ketamine demonstrates efficacy in treating chronic depression.
  • Limited understanding exists regarding the longevity of ketamine's benefits post-infusion.
  • Optimal patient guidance and risk mitigation require knowledge of challenges after ketamine cessation.

Observation:

  • This commentary discusses unexpected data from a pilot study.
  • The study focused on adjunctive ketamine infusion for treatment-resistant depression.

Findings:

  • The duration of ketamine's therapeutic effects after infusions are stopped is largely unknown.
  • Unexpected findings emerged from a pilot study examining ketamine for resistant depression.

Implications:

  • Understanding post-ketamine cessation challenges is crucial for clinical practice.
  • This knowledge can help clinicians guide patients and minimize risks associated with ketamine treatment.
  • Further research is needed to determine the optimal duration of ketamine's benefits.